Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Randomized Multicenter Pivotal Study of CDX-011 in Metastatic GPNMB Over-Expressing Triple-Negative Breast Cancer
2015-003693-33Phase 2Completed
- Sponsor
- Celldex Therapeutics
- Start
- Nov 2015
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of glembatumumab vedotin in breast cancer (2 arms), sponsored by Celldex Therapeutics. Primary endpoint: Progression-free survival. Started Nov 2015; status: completed.
02
Drugs
glembatumumab vedotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2015-003693-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003693-33.